Pre-treatment integrase inhibitor resistance is uncommon in ART-naïve individuals with HIV-1 subtype A1 and D infections in Uganda

OBJECTIVE: Dolutegravir (DTG) is now a preferred component of first-line antiretroviral therapy (ART). However, prevalence data on natural resistance to integrase inhibitors (INSTIs) in circulating non-subtype B HIV-1 in sub-Saharan Africa is scarce. Our objective is to report prevalence of pre-trea...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:AIDS
Main Authors: MCCLUSKEY, Suzanne M., KAMELIAN, Kimia, MUSINGUZI, Nicholas, KIGOZI, Simone, BOUM, Yap, BWANA, Mwebesa B., MUZOORA, Conrad, BRUMME, Zabrina L., CARRINGTON, Mary, CARLSON, Jonathan, FOLEY, Brian, HUNT, Peter W., MARTIN, Jeffrey N., BANGSBERG, David R., HARRIGAN, P. Richard, SIEDNER, Mark J., HABERER, Jessica E., LEE, Guinevere Q.
Formato: Artigo
Idioma:Inglês
Publicado em: 2021
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8102316/
https://ncbi.nlm.nih.gov/pubmed/33635845
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/QAD.0000000000002854
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados